When clinical trials fail to include racial and ethnic diversity into medical research, it can be harmful for large segments of the population. There is a real-world need for clinical oncology trials to adequately represent diverse racial and ethnic groups to better reflect the populations that are most likely to benefit from a drug.
NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)
Zolbetuximab + mFOLFOX6 as first-line treatment for patients with claudin-18.2+ / HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by Medical Affairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).
LARVOL VIEW Top 100 is a curated list of the most influential Digital Opinion Leaders (DOLs) in oncology on Twitter. Our methodology selects and ranks DOLs based on online influence, offline activity, and the opinions of other verified oncologists.
Coincides with launch of first social listening and sentiment analysis platform allowing researchers and pharma developers to tune into the cancer conversation with verified oncologists on Twitter
Read this summary of insights from our latest webinar with the MSL Society to discuss the experience of the MSL community nearly a year to the day since the COVID-19 pandemic shut down their ability to meet with KOLs in person.